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Background: Chronic use of inhaled anticholinergics by patients with chronic obstructive 
pulmonary disease (COPD) has raised long-term safety concerns, particularly cardiovascular. 
Glycopyrronium is a once-daily anticholinergic with greater receptor selectivity than previously 
available agents.
Methods: We assessed the safety of inhaled glycopyrronium using data pooled from two analysis 
sets, involving six clinical studies and over 4,000 patients with COPD who received one of the 
following treatments: glycopyrronium 50 µg, placebo (both delivered via the Breezhaler® device), 
or tiotropium 18 µg (delivered via the HandiHaler® device). Data were pooled from studies that 
varied in their duration and severity of COPD of the patients (ie, 12 weeks duration with 
patients having moderate or severe COPD; and 1 year duration with patients having severe 
and very severe COPD). Safety comparisons were made for glycopyrronium vs tiotropium or 
placebo. Poisson regression was used to assess the relative risk for either active drug or placebo 
(and between drugs where placebo was not available) for assessing the incidence of safety events. 
During post-marketing surveillance (PMS), safety was assessed by obtaining reports from vari-
ous sources, and disproportionality scores were computed using EMPIRICA™. In particular, the 
cardiac safety of glycopyrronium during the post-marketing phase was evaluated.
Results: The overall incidence of adverse events and deaths was similar across groups, while 
the incidence of serious adverse events was numerically higher in placebo. Furthermore, glyco-
pyrronium did not result in an increased risk of cerebro-cardiovascular events vs placebo. There 
were no new safety reports during the PMS phase that suggested an increased risk compared 
to results from the clinical studies. Moreover, the cardiac safety of glycopyrronium during the 
PMS phase was also consistent with the clinical data.
Conclusion: The overall safety profile of glycopyrronium was similar to its comparators indi-
cating no increase in the overall risk for any of the investigated safety end points.
Keywords: COPD, drug safety, glycopyrronium, post-marketing surveillance
Introduction
Chronic obstructive pulmonary disease (COPD) is characterized by airflow limitation 
that is not only progressive but also irreversible.1 Inhaled bronchodilators are regarded 
as foundational pharmacologic agents in the management of patients with COPD, pro-
viding not only short-term symptom relief but also reducing the exacerbation frequency 
and improving the quality of life.1 Long-acting muscarinic antagonists (LAMAs) (either 
alone or in combination with β-agonists) have been found to be effective bronchodilators 
for the treatment of patients with COPD.1 LAMAs may produce typical anticholinergic 
side effects such as dry mouth, urinary retention, constipation, and nausea.2 Inhaled 
tiotropium administered via soft mist inhaler at moderate and high dosages has been 
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associated with the risk of increased mortality, in particular, 
cardiovascular mortality.3 However, recent trials, such as the 
Tiotropium Safety and Performance in Respimat (TIOSPIR) 
study4 and other more recent analyses show a mortality risk 
similar to that of tiotropium in dry powder (HandiHaler®) 
formulation.5–9 Glycopyrronium (50 µg), delivered via the 
Breezhaler® device, is a once-daily (od) LAMA that is indi-
cated for management of patients with COPD. Its efficacy and 
safety have been demonstrated in various clinical studies.10 
It is known to be safe and well tolerated while exhibiting 
sustained 24-hour bronchodilation in patients with moderate-
to-severe COPD.11 As compared to tiotropium, it has a greater 
selectivity for the M3 vs M2 receptor, a property that may 
reduce the risk of cardiovascular adverse events (AEs).12 
Additionally, it has been shown to exhibit a rapid onset of 
action as compared to tiotropium, thus allowing for rapid and 
sustained symptom relief.11 To assess the safety of glycopyr-
ronium, we have undertaken an analysis of pooled safety data 
from clinical trials involving glycopyrronium along with 
the available data from post-marketing surveillance (PMS) 
review periods. In this pooled analysis, the safety of glycopyr-
ronium (delivered via the Breezhaler® device) and tiotropium 
(delivered via the HandiHaler® device) are compared with 
that of placebo. In the absence of placebo as a comparator, 
glycopyrronium is also compared with tiotropium.
Methods
All patients provided written informed consent. The com-
prehensive evaluation of the safety of glycopyrronium in the 
clinical studies was performed by using two distinct analysis 
sets that comprise the COPD core safety database (S-db) and 
the COPD long-term S-db. Studies with the recommended 
regimen of 50 µg glycopyrronium od, that were randomized 
double-blinded, placebo- and/or active-controlled, paral-
lel design, with exposure duration of at least 12 weeks in 
patients with moderate or severe COPD (including following 
studies: CNVA237A2304 [GLOW1],13 CNVA237A2303 
[GLOW2],14 CQVA149A2303 [SHINE],15 CNVA237A2314 
[GLOW5],16 and CNVA237A2309 [GLOW7])17 were 
included in the COPD core S-db. Within this database, data 
were pooled from all studies with similar disease severity, 
study design, and assessment methods utilized for evaluating 
AEs, deaths, and events of interest, with results adjusted for 
the length of exposure and reported as incidence (number 
of events per 100 patient treatment years [PTYs, sum of the 
duration of exposure over patients, in days/365.25 days]). 
The COPD long-term S-db included studies with an exposure 
duration of 1 year (CQVA149A2304 [SPARK],18 a double-
blinded, active-controlled, parallel design, and an exposure 
duration of at least 15 months in patients with severe and 
very severe COPD). The design of six individual studies 
included in the present analysis is summarized in Table 1. 
All the major adverse cardiovascular events and deaths 
were adjudicated by an external committee using predefined 
criteria. For the analysis of safety during the PMS review 
period, patient exposure to glycopyrronium was estimated 
based on the cumulative worldwide sales volume since its 
availability (September 28, 2012) for the approved 50 µg 
Table 1 Details of studies included in the pooled analysis
Study name Study 
design
Study 
duration
Patients 
randomized (N)
Patient population Treatment groups References
glOW1  
(CnVa237a2304)
r, DB, PC, Pg 26 weeks 822 Moderate-to-severe COPD 
(stage II and III, gOlD 2008)
glY 50 µg od 13
PBO od
glOW2  
(CnVa237a2303)
r, DB, and  
Ol (TIO),  
PC, Pg
52 weeks 1,066 Moderate-to-severe COPD 
(stage II and III, gOlD 2008)
glY 50 µg od 14
PBO od
Ol-TIO 18 µg od
glOW5  
(CnVa237a2314)
r, DD, Pg,  
Bl (TIO)
12 weeks 657 Moderate-to-severe COPD 
(stage II and III, gOlD 2010)
glY 50 µg od 16
Blinded TIO 18 µg od
glOW7  
(CnVa237a2309)
r, DB, PC,  
Pg
26 weeks 459 Moderate-to-severe COPD 
(stage II and III, gOlD 2010)
glY 50 µg od 17
PBO od
shIne*  
(CQVa149a2303)
DB and Ol  
(TIO), Pg, r,  
PC, aC
26 weeks 2,144 Moderate-to-severe COPD 
(stage II and III, gOlD 2008)
QVa149 110/50 µg od 15
InD 150 µg od
glY 50 µg od
Ol-TIO 18 µg od
PBO od
sParK*  
(CQVa149a2304)
DB and Ol  
(TIO), Pg, r
64 weeks 2,224 severe-to-very severe COPD 
(stage III and IV, gOlD 2008)
QVa149 110/50 µg od 18
glY 50 µg od
Ol-TIO 18 µg od
Note: *safety data for InD and QVa149 arms from the shIne study, and the QVa149 arm from the sParK study was not included in the current analysis.
Abbreviations: aC, active controlled; Bl, blinded; COPD, chronic obstructive pulmonary disease; DB, double-blind; DD, double-dummy; glOW, glycopyrronium bromide in 
COPD airWays clinical study; glY, glycopyrronium; InD, indacaterol; od, once daily; Ol, open-label; PBO, placebo; PC, placebo-controlled; Pg, parallel-group; r, randomized; 
TIO, tiotropium.
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dose delivered via the Breezhaler® device, until the cut-off 
date of March 28, 2014.
Patients
The protocols for all studies were approved by institutional 
review boards and ethics committees at participating centers, 
and were conducted in accordance with the Declaration of 
Helsinki and Good Clinical Practice. All patients provided 
written informed consent. Overall, the inclusion and exclu-
sion criteria for patients were similar across the studies. 
The study population in all the trials comprised patients 
who were at least 40 years of age, had a smoking history 
of at least 10 pack-years, with post-bronchodilator forced 
expiratory volume in 1 second (FEV
1
) to forced vital capac-
ity (FVC) ratio of 0.70 at screening, and diagnosed with 
moderate-to-severe COPD (Stage II or III according to the 
GOLD 2005 and 2008 criteria; post-bronchodilator FEV
1
 of 
30% and 80% of the predicted normal) with the excep-
tion of the SPARK study that enrolled patients with severe-
to-very severe COPD (Stage IV according to GOLD 2008; 
post-bronchodilator FEV
1 
50% predicted).18 Additionally, 
the clinical trial population also comprised patients with a 
medical history of stable cardiovascular disease.
safety assessment
All analyses were based on the safety population, defined 
as all patients who received at least one dose of study medi-
cation. Common AEs were summarized according to the 
Medical Dictionary for Regulatory Activities (MedDRA, 
version 16.0) hierarchy, including primary system organ 
class and preferred term. Only those events regarded as 
identified risks (narrow-angle glaucoma, bladder outflow 
obstruction and urinary retention, and use in patients with 
severe renal impairment) and potential risks (cerebrovas-
cular events, cardiovascular events including myocardial 
infarction and cardiac arrhythmias, atrial fibrillation, 
paradoxical bronchospasm, and medication errors) in the 
glycopyrronium (Seebri® Breezhaler®) risk management 
plan were searched through Standardized MedDRA Queries 
(SMQs) and Novartis MedDRA queries (NMQs). SMQs 
are collections of MedDRA (preferred) terms that relate 
to a defined medical condition, and allow identification of 
safety concerns, whereas NMQs are a customized group of 
search terms that define a medical concept for which there 
is no SMQ available.
The safety profile of glycopyrronium during the PMS 
review period was assessed by deriving AEs obtained from 
individual case study reports from health care profession-
als, consumers, scientific literature, spontaneous reports, 
competent authorities, noninterventional studies, and 
solicited sources such as compassionate use programs.
Furthermore, the safety of glycopyrronium during the 
PMS review period was also assessed by recording sponta-
neous voluntary reports of AEs. The EMPIRICA™ Signal 
System was used to calculate the disproportionality scores 
of the reported AEs using the Multi-item Gamma Poisson 
Shrinker (MGPS) algorithm. EMPIRICA™ is an advanced 
data mining tool used for automated detection and quanti-
fication of safety signals, applied to ARGUS™ (a Novartis 
global S-db that provides a comprehensive AE management 
system to support the Novartis pharmacovigilance program). 
The safety data coded by MedDRA (version 16.0) against 
events marked as “diagnosis” in ARGUS™ (leading events 
only) were retrieved by EMPIRICA™, after which all the 
AEs were assigned a statistical score.
statistical analysis
For each event of interest from the clinical data, an estimate 
of the risk ratio (RR) of incidence density (each respective 
active treatment vs placebo or active control), together with 
the 95% confidence interval (CI), was produced through a 
Poisson regression with treatment and study as class effects 
in the model.
For the assessment of safety during the PMS review 
period, the statistical scores (represented as Empirical Bayes 
Geometric Mean [EBGM]) were calculated using the MGPS 
algorithm. The assignment of EBGM scores was based on 
the association of glycopyrronium and AEs together (drug–
event combination) with a disproportionately high occur-
rence of reports, as compared to the proportion of reports in 
the entire ARGUS™ database for glycopyrronium and AEs 
independently. The lower 90% CI limit of EBGM (denoted 
as EB05) was used.
EB05 values 2 were considered as no technical sig-
nal and EMPIRICA™ alerted the reviewers if the report-
ing proportions of AEs were above the threshold value.19 
EMPIRICA™ calculates the disproportionality scores afresh 
each time to account for reconciliation of historic safety data. 
The disproportionality scores presented in this analysis were 
calculated on July 15, 2014.
Results
Patients and duration of their exposure 
to treatment
The analysis of the COPD core S-db included data from 
4,178 patients. The length of time for which the patients 
were exposed to the study drugs is tabulated in Table 2. 
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The majority of PTYs occurred in patients treated from 
3–12 months on these studies. The characteristics of the 
pooled patient population along with other clinical charac-
teristics were comparable across all the treatment groups 
(Table 3). There were a few noteworthy differences in the 
glycopyrronium group vs the other treatment groups: 1) by 
virtue of the way the studies were designed, the glycopyrro-
nium group exhibited approximately twofold higher patient 
exposure and enrollment than the tiotropium and placebo 
groups (Table 2); 2) more patients were 85 years (0.41%, 
0.19%, and 0.22%, for glycopyrronium, tiotropium, and 
placebo groups, respectively) (Table 3).
Patient exposure during PMs review 
period
The cumulative worldwide sale of glycopyrronium (at its 
approved dosage of 50 µg) during the PMS review period is 
estimated to be approximately 3,332 g of the active pharma-
ceutical ingredient. Consequently, patient exposure to gly-
copyrronium (since its first availability and until the cut-off 
date) is estimated to be approximately 182,562 PTYs.
aes during clinical studies
The five most common AEs in the glycopyrronium group 
were COPD worsening, nasopharyngitis, upper respiratory 
tract infection, cough, and headache (Table 4). Across 
all groups, COPD worsening was the most common AE 
that exhibited the least incidence in the glycopyrronium 
group. Generally, AEs were well balanced and the rates of 
occurrence of events for both glycopyrronium and tiotro-
pium treatment arms were similar to that of placebo. The 
only AEs (among the five most common AEs) observed 
in 2% of patients and that numerically increased with 
glycopyrronium were nasopharyngitis and headache, which 
occurred with an incidence similar to that of placebo and 
tiotropium.
Table 2 Duration of exposure to study drug after randomization (COPD core s-db)
Duration of exposure GLY 50 µg  
N=2,180
TIO 18 µg  
N=1,077
PBO  
N=921
Total PTYs 1,138.642 534.234 508.216
PTYs exposure, % of patients (Total PTYs)
1 day 0.41 (0.025) 0.37 (0.011) 0.54 (0.014)
2 days–2 weeks 1.38 (0.605) 1.11 (0.162) 2.39 (0.408)
2 weeks–1 month 1.83 (2.502) 1.67 (1.112) 4.13 (2.042)
1 month–3 months 18.62 (86.439) 30.64 (74.209) 6.51 (9.785)
3 months–6 months 12.25 (115.269) 10.68 (49.109) 12.49 (51.425)
6 months–12 months 52.34 (645.478) 41.13 (253.741) 58.09 (297.736)
12 months 13.17 (288.323) 14.39 (155.890) 15.85 (146.806)
Abbreviations: COPD, chronic obstructive pulmonary disease; glY, glycopyrronium; n, patients randomized; PBO, placebo; PTYs, patient treatment years; s-db, safety 
database; TIO, tiotropium.
Table 3 Characteristics of pooled clinical trial study population 
(COPD core s-db)
Patient 
characteristics
GLY 50 µg
N=2,180
TIO 18 µg
N=1,077
PBO
N=921
age
65 years 1,128 (51.74) 575 (53.39) 455 (49.40)
65–75 years 792 (36.33) 387 (35.93) 350 (38.00)
75–85 years 251 (11.51) 113 (10.49) 114 (12.38)
85 years 9 (0.41) 2 (0.19) 2 (0.22)
sex
Male 1,689 (77.48) 776 (72.05) 702 (76.22)
Female 491 (22.52) 301 (27.95) 219 (23.78)
race
Caucasian 1,345 (61.70) 786 (72.98) 557 (60.48)
Black 28 (1.28) 17 (1.58) 15 (1.63)
asian 758 (34.77) 241 (22.38) 331 (35.94)
Other 49 (2.25) 33 (3.06) 18 (1.95)
number of CCV risk factors at baseline
0 217 (9.95) 79 (7.34) 90 (9.77)
1 571 (26.19) 255 (23.68) 236 (25.62)
2 570 (26.15) 286 (26.56) 243 (26.38)
3 822 (37.71) 457 (42.43) 352 (38.22)
COPD severity
Mild 2 (0.09) 1 (0.09) 0 (0)
Moderate 1,302 (59.72) 661 (61.37) 579 (62.87)
severe 868 (39.82) 414 (38.44) 338 (36.70)
Very severe 8 (0.37) 0 (0) 4 (0.43)
steroid use
none 948 (43.49) 481 (44.66) 427 (46.36)
ICs 1,220 (55.96) 588 (54.60) 491 (53.31)
OCs 3 (0.14) 2 (0.19) 1 (0.11)
ICs and OCs 9 (0.41) 6 (0.56) 2 (0.22)
Baseline diabetes 
condition
274 (12.57) 141 (13.09) 119 (12.92)
Note: Values are n (%).
Abbreviations: CCV, cerebrovascular and cardiovascular; COPD, chronic obstructive 
pulmonary disease; glY, glycopyrronium; ICs, inhaled corticosteroids; n, patients 
randomized; OCs, oral corticosteroids; PBO, placebo; s-db, safety database; TIO, 
tiotropium.
Overall, the cardiovascular AE rate was similar for 
glycopyrronium and placebo although atrial fibrillation was 
seen more often with glycopyrronium. The most commonly 
occurring LAMA-specific AEs were dizziness, dry mouth, 
constipation, nausea, and pyrexia. In general, these events 
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Table 4 Incidence of most common aes (per 100 PTYs) in clinical studies sorted by primary system organ class and preferred term 
(10 events/100 PTYs for glY) (COPD core s-db)
Primary system organ class,  
preferred term
GLY 50 µg
N=2,180
TIO 18 µg
N=1,077
PBO
N=921
Patients with 1 ae, (%) 1,274 (58.44) 607 (56.36) 586 (63.63)
number of aes/100 PTYs 342.952 371.373 393.927
respiratory, thoracic, and mediastinal disorders
Total 1,221 (107.233) 682 (127.659) 709 (139.508)
COPD worsening 868 (76.231) 510 (95.464) 538 (105.860)
Cough 87 (7.641) 39 (7.300) 39 (7.674)
Dyspnea 53 (4.655) 19 (3.556) 29 (5.706)
Oropharyngeal pain 27 (2.371) 14 (2.621) 16 (3.148)
sinus congestion 16 (1.405) 5 (0.936) 2 (0.394)
Dysphonia 14 (1.230) 7 (1.310) 5 (0.984)
nasal congestion 12 (1.054) 8 (1.497) 8 (1.574)
epistaxis 11 (0.966) 5 (0.936) 2 (0.394)
Infections and infestations
Total 1,029 (90.371) 546 (102.202) 537 (105.664)
nasopharyngitis 209 (18.355) 79 (14.788) 93 (18.299)
Upper rTI 170 (14.930) 73 (13.664) 100 (19.677)
lower rTI 55 (4.830) 34 (6.364) 28 (5.509)
Bronchitis 43 (3.776) 29 (5.428) 24 (4.722)
sinusitis 42 (3.689) 22 (4.118) 20 (3.935)
Urinary tract infection 42 (3.689) 23 (4.305) 13 (2.558)
Viral upper rTI 42 (3.689) 35 (6.551) 38 (7.477)
Influenza 34 (2.986) 18 (3.369) 13 (2.558)
Pneumonia 31 (2.723) 16 (2.995) 22 (4.329)
Pharyngitis 20 (1.756) 17 (3.182) 8 (1.574)
rhinitis 19 (1.669) 7 (1.310) 4 (0.787)
Cellulitis 12 (1.054) 6 (1.123) 6 (1.181)
Oral candidiasis 12 (1.054) 7 (1.310) 6 (1.181)
gastroenteritis 11 (0.966) 3 (0.562) 6 (1.181)
gastroenteritis viral 10 (0.878) 4 (0.749) 3 (0.590)
rTI 10 (0.878) 5 (0.936) 3 (0.590)
nervous system disorders
Total 205 (18.004) 82 (15.349) 83 (16.332)
headache 82 (7.202) 38 (7.113) 33 (6.493)
syncope 14 (1.230) 0 4 (0.787)
Cardiac disorders
Total 104 (9.134) 34 (6.364) 55 (10.822)
Atrial fibrillation 15 (1.317) 4 (0.749) 2 (0.394)
angina pectoris 10 (0.878) 5 (0.936) 10 (1.968)
eye disorders
Total 43 (3.776) 23 (4.305) 19 (3.739)
Cataract 10 (0.878) 7 (1.310) 2 (0.394)
gastrointestinal disorders
Total 263 (23.098) 140 (26.206) 138 (27.154)
Diarrhea 29 (2.547) 10 (1.872) 18 (3.542)
Toothache 16 (1.405) 5 (0.936) 4 (0.787)
Dyspepsia 15 (1.317) 6 (1.123) 4 (0.787)
abdominal pain 13 (1.142) 8 (1.497) 5 (0.984)
Vomiting 13 (1.142) 10 (1.872) 11 (2.164)
Gastroesophageal reflux disease 12 (1.054) 9 (1.685) 10 (1.968)
Note: Values are total number of aes (aes/100 PTYs) unless otherwise stated.
Abbreviations: aes, adverse events; COPD, chronic obstructive pulmonary disease; glY, glycopyrronium; n, patients randomized; PBO, placebo; PTYs, patient treatment 
years; rTI, respiratory tract infection; s-db, safety database; TIO, tiotropium.
occurred most commonly in the placebo group, with only dry 
mouth, constipation, and throat irritation modestly increasing 
with glycopyrronium (Table 5).
adjudicated deaths and serious 
aes reported during clinical phase
The incidence of deaths and serious AEs (SAEs) adjusted per 
PTYs is listed in Table 6. The occurrence of deaths (exposure 
adjusted) was comparable across groups. Respiratory cause 
was the leading reason for deaths among the treatment groups, 
and was lowest in the glycopyrronium group. Furthermore, 
the RR for respiratory deaths relative to placebo was slightly 
lower for glycopyrronium (RR: 1.059 vs placebo; 95% 
CI – 0.368, 3.047) than for tiotropium (RR: 1.928 vs placebo; 
95% CI – 0.471, 7.892) (Table 6). The overall incidence of 
SAEs (exposure adjusted) in glycopyrronium and tiotropium 
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Table 5 Incidence of aes most commonly associated with 
LAMAs, classified according to primary system organ class and 
preferred term (COPD core s-db)
Primary system organ  
class, preferred term
GLY 50 µg
N=2,180
TIO 18 µg
N=1,077
PBO
N=921
Total PTYs 1,138.642 534.234 508.216
nervous system disorders
Dizziness 25 (2.196) 9 (1.685) 13 (2.558)
renal and urinary disorders
Urinary retention 4 (0.351) 2 (0.374) 0
gastrointestinal disorders
Dry mouth 33 (2.898) 14 (2.621) 10 (1.968)
Constipation 22 (1.932) 5 (0.936) 9 (1.771)
nausea 16 (1.405) 11 (2.059) 11 (2.164)
general disorders
Pyrexia 35 (3.074) 9 (1.685) 25 (4.919)
eye disorders
Vision blurred 5 (0.439) 1 (0.187) 3 (0.590)
Dry eye 3 (0.263) 2 (0.374) 1 (0.197)
respiratory disorders
Throat irritation 11 (0.966) 3 (0.562) 4 (0.787)
rhinorrhea 5 (0.439) 6 (1.123) 10 (1.968)
Cardiac disorders
Tachycardia 2 (0.176) 1 (0.187) 4 (0.787)
Palpitations 5 (0.439) 2 (0.374) 4 (0.787)
Note: Values are total number of aes (aes/100 PTYs).
Abbreviations: aes, adverse events; COPD, chronic obstructive pulmonary 
disease; glY, glycopyrronium; laMas, long-acting muscarinic antagonists; n, patients 
randomized; PBO, placebo; PTYs, patient treatment years; s-db, safety database; TIO, 
tiotropium.
Table 6 adjudicated deaths, and saes (0.2 events/100 PTYs 
for glY) (COPD core s-db)
Primary system organ 
class, preferred term
GLY 50 µg
N=2,180
TIO 18 µg
N=1,077
PBO
N=921
Total deaths, n (%) 11 (0.23) 5 (0.46) 5 (0.54)
risk ratio 1.059 1.928
95% CI (lower, upper limit) 0.368, 3.047 0.471, 7.892
P-value 0.9160 0.3610
Deaths/100 PTYs 0.966 0.936 0.984
Cardiovascular 0.263 0.187 0.197
respiratory 0.351 0.562 0.590
Cancer 0.176 0.187 0
Unknown 0 0 0.197
Other causes 0.176 0 0
Patients with 1 sae 163 72 94
number of saes/100 PTYs 25.205 20.965 35.615
respiratory, thoracic, and mediastinal disorders
Total 84 (7.377) 37 (6.926) 61 (12.003)
COPD worsening 54 (4.742) 28 (5.241) 48 (9.445)
respiratory failure 7 (0.615) 2 (0.374) 5 (0.984)
Dyspnea 3 (0.263) 0 2 (0.394)
Pneumothorax 3 (0.263) 2 (0.374) 0
acute respiratory failure 2 (0.176) 2 (0.374) 0
Infections and infestations
Total 54 (4.742) 25 (4.680) 35 (6.887)
Pneumonia 19 (1.669) 9 (1.685) 15 (2.951)
Bronchitis 6 (0.527) 2 (0.374) 1 (0.197)
Upper respiratory tract  
infection bacterial
5 (0.439) 2 (0.374) 5 (0.984)
lower respiratory  
tract infection
3 (0.263) 1 (0.187) 3 (0.590)
Cellulitis 3 (0.263) 1 (0.187) 1 (0.197)
Cardiac disorders
Total 34 (2.986) 5 (0.936) 16 (3.148)
Atrial fibrillation 8 (0.703) 0 0
acute coronary syndrome 3 (0.263) 0 0
Cardiac failure congestive 3 (0.263) 1 (0.187) 1 (0.197)
Myocardial infarction 3 (0.263) 1 (0.187) 1 (0.197)
angina pectoris 2 (0.176) 1 (0.187) 3 (0.590)
nervous system disorders
Total 16 (1.405) 8 (1.497) 6 (1.181)
syncope 6 (0.527) 0 1 (0.197)
Transient ischemic attack 4 (0.351) 0 1 (0.197)
Notes: Values are total number of events (events/100 PTYs) unless otherwise 
stated. risk ratio values are represented as active vs placebo.
Abbreviations: COPD, chronic obstructive pulmonary disease; CI, confidence 
interval; glY, glycopyrronium; n, patients randomized; PBO, placebo; PTYs, 
patient treatment years; saes, serious adverse events; s-db, safety database; TIO, 
tiotropium.
groups was lower than that in the placebo group. The most 
commonly occurring SAE was COPD worsening, which was 
the lowest in the glycopyrronium group.
The incidence of SAEs by preferred term for gastrointes-
tinal, vascular, and renal/urinary disorders was lower than 
the threshold (0.2 events/100 PTYs for glycopyrronium). 
The overall frequency of occurrence (events/100 PTYs) 
of SAEs in the various treatment arms was as follows: 
glycopyrronium (gastrointestinal, 1.317; vascular, 0.790; 
renal/urinary, 0.439); tiotropium (gastrointestinal, 1.872; 
vascular, 0; renal/urinary, 0.187); and placebo (gastrointes-
tinal, 2.558; vascular, 0.394; renal/urinary, 0.787).
Cerebrovascular and cardiovascular 
events during clinical phase
The frequency of occurrence of cerebrovascular and car-
diovascular (CCV) events are shown in Table 7 (also refer 
Supplementary materials, Tables S1–S4). Glycopyrronium 
did not result in any increased risk for cardiovascular events 
in patients in comparison with placebo. Cumulative assess-
ment of the clinical data did not establish any underlying 
association of cardiovascular events and glycopyrronium. 
Compared to placebo, both actives, glycopyrronium (RR: 
3.805 vs placebo; 95% CI – 0.875, 16.550) and tiotropium 
(RR: 1.550, 95% CI – 0.253, 9.495), exhibited an increase in 
the exposure-adjusted incidence of atrial fibrillation, although 
these were not statistically significant (Tables 7, S1 and S2). 
The RR for cerebrovascular events for glycopyrronium 
(RR: 1.95 vs placebo; 95% CI – 0.553, 6.870) (95% CI of 
0.553, 6.870) was lower than that for tiotropium (RR: 2.62 
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Table 7 Incidence of CCV-related AEs and FAEs (defined by 
sMQ) adjusted for exposure with risk ratio and 95% CI (COPD 
core s-db)
Preferred term GLY 50 µg
N=2,180
TIO 18 µg
N=1,077
PBO
N=921
Cardiac arrhythmias
number (episodes/ 
100 PTYs)
51 (4.48) 24 (4.49) 25 (4.92)
relative risk 0.909 0.770
95% CI (lower, upper 
limit)
0.562, 1.472 0.431, 1.374
P-value 0.6990 0.3758
Myocardial infarction or ischemic heart disease
number (episodes/ 
100 PTYs)
24 (2.11) 7 (1.31) 19 (3.74)
relative risk 0.585 0.352
95% CI (lower, upper 
limit)
0.320, 1.071 0.144, 0.863
P-value 0.0824 0.0225
Atrial fibrillation
number (episodes/ 
100 PTYs)
16 (1.41) 3 (0.56) 2 (0.39)
relative risk 3.805 1.550
95% CI (lower, upper 
limit)
0.875, 16.550 0.253, 9.495
P-value 0.0748 0.6354
Cardiac failure
number (episodes/ 
100 PTYs)
11 (0.97) 2 (0.37) 8 (1.57)
relative risk 0.618 0.264
95% CI (lower, upper 
limit)
0.246, 1.550 0.052, 1.335
P-value 0.3045 0.1073
Cerebrovascular events
number (episodes/ 
100 PTYs)
13 (1.14) 7 (1.31) 3 (0.59)
relative risk 1.950 2.620
95% CI (lower, upper 
limit)
0.553, 6.870 0.626, 10.976
P-value 0.2986 0.1875
Patients with 1  
CCV-related Faes
1 1 1
number of CCV-
related Faes/100 PTYs
0.088 0.187 0.197
Cardiopulmonary 
failure
0 0 1 (0.197)
Thalamus hemorrhage 1 (0.088) 0 0
Myocardial infarction 0 1 (0.187) 0
Notes: CCV condition determined based on the following predefined search 
criteria: Cerebrovascular disorders (sMQ) (narrow); Cardiac arrhythmia terms 
(including bradyarrhythmias and tachyarrhythmias) (sMQ) (broad); Myocardial 
infarction (sMQ) (narrow); Other ischemic heart disease (sMQ) (narrow); 
Cardiac failure (sMQ) (narrow); sudden death (PT); sudden cardiac death (PT). 
risk ratio values are represented as active vs placebo; episodes/100 PTYs =100× 
(n/total PTYs). Values are number of aes/100 PTYs (n/total PTYs) ×100.
Abbreviations: aes, adverse events; CCV, cerebrovascular and cardiovascular; 
CI, confidence interval; COPD, chronic obstructive pulmonary disease; FAEs, fatal 
aes; glY, glycopyrronium; n, patients randomized; PBO, placebo; PTYs, patient 
treatment years; rr, risk ratio; s-db, safety database; sMQ, standardized MedDra 
Query; TIO, tiotropium.
vs placebo; 95% CI – 0.626, 10.976) (although at wide CI). 
The glycopyrronium arm exhibited the least incidence of 
CCV-related fatal AEs (exposure-adjusted). The incidence 
of angioedema (exposure-adjusted and defined as Standard 
MedDRA Query narrow search) for glycopyrronium was 
similar to that for placebo and tiotropium albeit with numeri-
cally lower RR for glycopyrronium: (RR: 1.183 vs placebo; 
95% CI – 0.371, 3.773) compared with tiotropium (RR: 1.474 
vs placebo; 95% CI – 0.394, 5.519) (Table S4). Overall, 
the cardiovascular AE rate was similar for glycopyrronium 
and placebo, although atrial fibrillation events were seen 
more often with glycopyrronium, although not statistically 
significant.
long-term CCV safety (in patients with 
severe-to-very severe airflow limitation)
The long-term clinical study enrolled patients at risk for 
exacerbations (defined as patients with severe-to-very severe 
airflow limitation, Stage III or IV according to GOLD 2008 
criteria) and a documented history of at least one exacerbation 
in the previous 12 months requiring treatment with systemic 
corticosteroids or antibiotics, or both.
The exposure-adjusted incidence of events related 
to myocardial infarction, ischemic heart disease, and 
cardiac arrhythmia was numerically slightly higher for 
glycopyrronium as compared with tiotropium (Table 8); 
however, wide CIs preclude any clinical or statistical 
significance. The low number of observed cases did not 
allow meaningful comparison. The RR for the occurrence 
of cardiac failure was low for glycopyrronium (RR: 
0.504 vs tiotropium; 95% CI – 0.227, 1.122). The inci-
dence of cerebrovascular events (exposure-adjusted) 
during the long-term period was low compared to that 
of cardiovascular events, and also similar for tiotropium 
and glycopyrronium.
safety during PMs review period
Table 9 summarizes the incidence of SAEs and non-SAEs 
during the PMS review phase (ie, from September 28, 2012 
to March 28, 2014). By system organ class, the three most 
commonly occurring events during the PMS phase (in the 
order of decreasing frequency) were respiratory disorders, 
followed by gastrointestinal disorders and nervous system 
disorders. Cough was the most commonly occurring event 
across all organ system classes during the PMS review 
period; compared with data from clinical studies, glycopyr-
ronium did not increase the risk of AEs and SAEs in patients 
during PMS.
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The cardiovascular safety profile of glycopyrronium was 
found to be consistent with the approved label as supported 
by data from the clinical development program. Furthermore, 
there was no increase in the severity or incidence of reports 
related to atrial fibrillation with identification of no new 
safety concern compared with safety information on the 
package insert of Seebri® Breezhaler®.
safety analysis during PMs review period 
using eMPIrICa™
Based on the safety data retrieved using EMPIRICA™, 
EB05 disproportionality scores for all AEs were less than 
the threshold value (EB05 2) except for urinary retention 
and cardiac arrhythmia, which are well-known side effects 
of anticholinergic compounds (Table 10).
Table 8 Incidence of cerebrovascular and cardiovascular aes 
(defined by SMQ) during long-term (1 year) period and 
adjusted for exposure with risk ratio and 95% CI (COPD long-
term s-db)
Preferred term GLY 50 µg
N=740
TIO 18 µg
N=737
Cardiac arrhythmias
number (episodes/100 PTYs) 29 (3.45) 16 (1.89)
relative risk 1.828
95% CI (lower, upper limit) 0.993, 3.365
P-value 0.0528
Myocardial infarction or ischemic heart disease
number (episodes/100 PTYs) 26 (3.09) 19 (2.24)
relative risk 1.380
95% CI (lower, upper limit) 0.764, 2.493
P-value 0.2859
Atrial fibrillation
number (episodes/100 PTYs) 14 (1.66) 9 (1.06)
relative risk 1.569
95% CI (lower, upper limit) 0.679, 3.624
P-value 0.2919
Cardiac failure
number (episodes/100 PTYs) 9 (1.07) 18 (2.12)
relative risk 0.504
95% CI (lower, upper limit) 0.227, 1.122
P-value 0.0935
Cerebrovascular events
number (episodes/100 PTYs) 9 (1.07) 10 (1.18)
relative risk 0.908
95% CI (lower, upper limit) 0.369, 2.234
P-value 0.8329
Notes: CCV condition determined based on the following predefined SMQ search 
criteria: angioedema (narrow scope); Cerebrovascular disorders (narrow); Cardiac 
arrhythmia (including bradyarrhythmias and tachyarrhythmias) (broad); Myocardial 
infarction (narrow); Other ischemic heart disease (narrow). risk ratio values are 
represented as glycopyrronium vs tiotropium. 
Abbreviations: aes, adverse events; CCV, cerebrovascular and cardiovascular; 
CI, confidence interval; COPD, chronic obstructive pulmonary disease; GLY, 
glycopyrronium; n, patients randomized; PTYs, patient treatment years; rr, risk 
ratio; s-db, safety database; sMQ, standardized MedDra Query; TIO, tiotropium.
Table 9 summary of serious and nonserious adverse reactions 
during PMs sorted by primary system organ class and preferred 
term
Primary system organ  
class, preferred term
Total  
reportsa
Reporting  
frequencyb
respiratory, thoracic, and mediastinal disorders
Total 263 0.144
Cough 59 0.032
Dyspnea 55 0.030
epistaxis 25 0.014
Dysphonia 17 0.009
Throat irritation 17 0.009
Oropharyngeal pain 16 0.009
gastrointestinal disorders
Total 223 0.122
Dry mouth 38 0.021
Diarrhea 32 0.018
nausea 24 0.013
Upper abdominal pain 16 0.009
Constipation 12 0.007
nervous system disorders
Total 106 0.058
headache 43 0.024
Dizziness 13 0.007
Dysgeusia 12 0.007
skin and subcutaneous tissue disorders
Total 81 0.044
rash 22 0.012
Pruritus 11 0.006
Cardiac disorders
Total 74 0.041
Palpitations 23 0.013
Tachycardia 13 0.007
renal and urinary disorders
Total 72 0.039
Urinary retention 18 0.010
Dysuria 16 0.009
Pollakiuria 11 0.006
Musculoskeletal disorders
Total 71 0.039
Myalgia 17 0.009
Pain in extremity 14 0.008
eye disorders
Total 66 0.036
Visual impairment 12 0.007
Psychiatric disorders
Total 44 0.024
Insomnia 16 0.009
Notes: aIncludes serious and nonserious adverse reactions. bIncidence is reported 
only for events that occurred with a frequency of 0.007/100 PTYs.
Abbreviations: PMs, post-marketing surveillance; PTYs, patient treatment years.
Discussion
Analyzing the pooled data from clinical studies and the PMS 
review period of glycopyrronium offers the first opportunity 
for a comprehensive assessment of AEs and SAEs related 
to its use in COPD. The importance of this relates to the 
possible adverse consequences of LAMA use in this setting. 
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For example, cardiovascular safety concerns had been raised 
with the use of tiotropium in widespread usage since its 
launch in January 2004, evident primarily when used via the 
Respimat® device.3,20 A comprehensive examination of drug 
safety often continues beyond the clinical phase leading up 
to the PMS period, thus providing an opportunity to not only 
capture the occurrence of expected safety concerns but also 
those that are infrequent or may be unexpected. The analysis 
of the data from various clinical studies and the PMS review 
period showed that glycopyrronium did not increase the risk 
for any investigated safety points in comparison to placebo, 
although the incidence of atrial fibrillation was numerically 
higher with glycopyrronium vs placebo. Anticholinergics 
are known to be associated with cardiovascular AEs, such as 
arrhythmias.2 The analysis also indicates that safety profile 
of glycopyrronium was similar to that of tiotropium. COPD 
worsening was the most common AE and SAE reported in 
clinical trials, and occurred least frequently with glycopyr-
ronium vs comparators. The long-term safety of glycopyr-
ronium was also very similar to that of tiotropium.
There are some limitations to our analysis. In particular, 
clinical trials have predefined criteria for inclusion and exclu-
sion of patients that may not always replicate the real-life 
setting or may not represent clinical characteristics of patients 
with COPD who receive the approved treatment. In addition, 
our reliance on incidence rates may have confounded our anal-
ysis. The incidence rate of AEs is calculated as the total number 
of episodes divided by the total patient years. Although this 
method can account for differences in exposure and appears 
appropriate for use when the data from patient population is 
pooled from studies with different exposure duration, there 
is an implicit assumption that each AE does not increase or 
decrease in frequency and/or severity over time. This may not 
be a valid assumption in all the cases. Additionally, the hygro-
scopic nature of tiotropium makes it challenging to remove the 
powder from the capsule (marked with manufacturer’s logo) to 
a placebo capsule. In the GLOW2, SHINE (both from COPD 
core S-db), and SPARK (COPD long-term S-db) studies, 
tiotropium was dosed open-label, which may have influenced 
patient expectations. It is possible that in open-label studies, 
patients receiving the unblinded treatment may over report 
more favorable outcomes or, under report unfavorable safety 
signals. Finally, there could also be potential under reporting 
of AEs available in the ARGUS™ database, which are used 
as background incidence for calculation.
The comprehensive analysis of safety of glycopyrronium 
presented here has numerous strengths since it pools data 
from five randomized clinical trials (from the COPD core 
S-db) representing more than 4,000 patients with moderate-
to-severe COPD. Our analysis also presents long-term safety 
(1 year) of glycopyrronium, specifically in patients with 
severe-to-very severe COPD (from the COPD long-term 
S-db), who are at an increased risk of exacerbation.1
Furthermore, the inclusion and exclusion criteria across 
all studies were similar and so were the clinical characteristics 
of recruited patients (with the exception of the SPARK study 
to assess long-term safety). The pooled studies also exhibit an 
almost identical method of collection of AE reports and allow 
for the analysis of cardiovascular safety in patients with COPD 
with different exposure duration. Along with the pooled data 
from clinical studies, the safety of glycopyrronium was also 
evaluated during the PMS review period, particularly its 
cardiac safety. This provides a complete picture of the safety 
profile of glycopyrronium. Finally, the EMPIRICA™ data 
mining tool allows using an innovative approach for assess-
ing drug safety for detection of statistics of disproportionate 
reporting for recognizing emerging trends in spontaneous AE 
reports for effective pharmacovigilance.
Conclusion
The analysis of pooled data from various clinical studies 
did not reveal any increase in the overall risk for any of the 
investigated safety end points. Glycopyrronium exhibited a 
comparable safety profile to tiotropium and placebo. Further-
more, the safety of glycopyrronium during the PMS review 
period was consistent with its approved label and did not 
indicate any clinically important safety findings, indicating 
a favorable overall benefit–risk balance.
Table 10 statistical scores for aes of clinical interest during the 
PMs phase
Preferred term  
(leading event)
EB05 disproportionality 
scores
angioedema (sMQ-narrow) 0.787
angioedema (sMQ-broad) 0.739
Atrial fibrillation 1.768
Cardiac arrhythmia (nonspecific SMQ-broad) 0.777
Cardiac arrhythmia terms* (sMQ-broad) 1.398
Cardiac failure (sMQ-narrow) 0.598
Cardiac failure (sMQ-broad) 0.417
glaucoma (sMQ-narrow) 0.99
glaucoma (sMQ-broad) 0.443
Myocardial infarction (sMQ-narrow) 0.223
Myocardial infarction (sMQ-broad) 0.277
Urinary retention 5.699
Urinary tract disorder 0.264
Notes: *Including bradyarrhythmias and tachyarrhythmias. eB05 disproportionality 
scores represent the lower 90% CI limit of empirical Bayes geometric Mean.
Abbreviations: aes, adverse events; PMs, post-marketing surveillance; sMQ, 
standardized MedDra Query.
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Supplementary materials
Table S1 Number of patients with atrial fibrillation and flutter (adjudicated) adjusted for exposure (COPD core S-db)
GLY 50 µg TIO 18 µg PBO
Overall
Total population 2,180 1,077 921
Patients with 1 event 44 23 14
Total patient years 1,138.642 534.234 508.216
Patients/100 PTYs 3.864 4.305 2.755
new onset
Total population 2,124 1,049 900
Patients with 1 event 10 5 1
Total patient years 1,111.373 519.661 498.042
Patients/100 PTYs 0.900 0.962 0.201
recurrent
Total population 56 28 21
Patients with 1 event 34 18 13
Total patient years 27.269 14.574 10.174
Patients/100 PTYs 124.684 123.511 127.779
Abbreviations: COPD, chronic obstructive pulmonary disease; glY, glycopyrronium; PBO, placebo; PTYs, patient treatment years; s-db, safety database; TIO, tiotropium.
Table S2 Number of patients with atrial fibrillation and flutter (adjudicated) adjusted for exposure for long-term safety assessment 
(COPD long-term s-db)
GLY 50 µg TIO 18 µg
Overall
Total population 740 737
Patients with 1 event 21 24
Total patient years 841.645 848.780
Patients/100 PTYs 2.495 2.828
new onset
Total population 717 714
Patients with 1 event 6 8
Total patient years 817.615 825.944
Patients/100 PTYs 0.734 0.969
recurrent
Total population 23 23
Patients with 1 event 15 16
Total patient years 24.030 22.836
Patients/100 PTYs 62.422 70.064
Abbreviations: COPD, chronic obstructive pulmonary disease; glY, glycopyrronium; PTYs, patient treatment years; s-db, safety database; TIO, tiotropium. 
Table S3 Incidence of CCV-related aes (per 100 patient years) in clinical studies sorted by primary system organ class and preferred 
term (10 events for glY) (COPD core s-db)
Primary system organ class,  
preferred term
GLY 50 µg
N=2,180
TIO 18 µg
N=1,077
PBO
N=921
Patients with 1 ae 83 31 37
number of aes/100 PTYs 8.695 7.487 10.822
Cardiac disorders
Total 83 (7.289) 27 (5.054) 44 (8.658)
Atrial fibrillation 15 (1.317) 4 (0.749) 2 (0.394)
angina pectoris 10 (0.878) 5 (0.936) 10 (1.968)
Cardiac failure congestive 6 (0.527) 1 (0.187) 2 (0.394)
Ventricular extrasystoles 6 (0.527) 4 (0.749) 2 (0.394)
(Continued)
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Table S3 (Continued)
GLY 50 µg
N=2,180
TIO 18 µg
N=1,077
PBO
N=921
Atrioventricular block first-degree 4 (0.351) 1 (0.187) 2 (0.394)
acute coronary syndrome 3 (0.263) 0 0
Cardiac failure 3 (0.263) 1 (0.187) 0
Coronary artery disease 3 (0.263) 0 2 (0.394)
Myocardial infarction 3 (0.263) 1 (0.187) 2 (0.394)
Myocardial ischemia 3 (0.263) 0 1 (0.197)
supraventricular extrasystoles 3 (0.263) 3 (0.562) 3 (0.590)
supraventricular tachycardia 3 (0.263) 1 (0.187) 4 (0.787)
Atrial flutter 2 (0.176) 0 4 (0.787)
Bundle branch block left 2 (0.176) 2 (0.374) 0
Bundle branch block right 2 (0.176) 0 0
sinus tachycardia 2 (0.176) 2 (0.374) 2 (0.394)
acute myocardial infarction 1 (0.088) 0 1 (0.197)
arteriosclerosis coronary artery 1 (0.088) 0 1 (0.197)
atrial tachycardia 1 (0.088) 0 0
atrioventricular block 1 (0.088) 0 0
atrioventricular dissociation 1 (0.088) 0 0
Cor pulmonale 1 (0.088) 0 2 (0.394)
Cor pulmonale chronic 1 (0.088) 0 0
long QT syndrome 1 (0.088) 0 0
nodal arrhythmia 1 (0.088) 0 0
sick sinus syndrome 1 (0.088) 0 0
sinus bradycardia 1 (0.088) 0 1 (0.197)
Tachyarrhythmia 1 (0.088) 0 1 (0.197)
Wandering pacemaker 1 (0.088) 0 0
angina unstable 0 0 1 (0.197)
arrhythmia 0 1 (0.187) 0
Cardiac failure acute 0 0 1 (0.197)
Cardiopulmonary failure 0 0 1 (0.197)
Coronary artery insufficiency 0 1 (0.187) 0
right ventricular failure 0 0 1 (0.197)
Ventricular tachycardia 0 0 0
nervous system disorders
Total 13 (1.142) 6 (1.123) 3 (0.590)
Transient ischemic attack 5 (0.439) 0 2 (0.394)
Carotid artery stenosis 2 (0.176) 0 0
Carotid artery disease 1 (0.088) 0 0
Cerebral arteriosclerosis 1 (0.088) 0 0
Cerebral infarction 1 (0.088) 0 0
Cerebrovascular accident 1 (0.088) 2 (0.374) 0
Thalamus hemorrhage 1 (0.088) 0 0
Vertebrobasilar insufficiency 1 (0.088) 0 1 (0.197)
hemorrhagic stroke 0 1 (0.187) 0
Ischemic stroke 0 2 (0.374) 0
spinal hematoma 0 1 (0.187) 0
respiratory, thoracic, and mediastinal disorders
Total 0 0 1 (0.197)
Pulmonary edema 0 0 1 (0.197)
Injury, poisoning, and procedural complications
Total 0 1 (0.187) 0
extradural hematoma 0 1 (0.187) 0
Investigations
Total 3 (0.263) 6 (1.123) 7 (1.377)
heart rate irregular 2 (0.176) 0 0
electrocardiogram QT prolonged 1 (0.088) 6 (1.123) 7 (1.377)
Note: Values in parentheses are total number of aes per 100 PTYs.
Abbreviations: aes, adverse events; CCV, cerebrovascular and cardiovascular; COPD, chronic obstructive pulmonary disease; glY, glycopyrronium; n, patients 
randomized; PBO, placebo; PTYs, patient treatment years; s-db, safety database; TIO, tiotropium.
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Table S4 Incidence of angioedema (defined by SMQ)-narrow AE episodes adjusted for exposure by primary system organ class and 
preferred term with rr and 95% CI (COPD core s-db)
GLY 50 µg  
N=2,180
TIO 18 µg  
N=1,077
PBO  
N=921
Patients with 1 event 9 4 4
episodes/100 PTYs 0.878 1.123 0.787
risk ratio 1.183 1.474
95% CI (lower, upper limit) 0.371, 3.773 0.394, 5.519
P-value 0.7762 0.5643
eye disorders
Total 1 (0.088) 0 1 (0.197)
Periorbital edema 1 (0.088) 0 0
eye swelling 0 0 1 (0.197)
gastrointestinal disorders
Total 0 2 (0.374) 1 (0.197)
lip edema 0 2 (0.374) 0
Palatal edema 0 0 1 (0.197)
skin and subcutaneous tissue disorders
Total 9 (0.790) 4 (0.749) 2 (0.394)
Urticaria 9 (0.790) 3 (0.562) 2 (0.394)
angioedema 0 1 (0.187) 0
Notes: risk ratio values are represented as active vs placebo. Values in parentheses are total number of aes per 100 PTYs.
Abbreviations: AE, adverse event; CI, confidence interval; COPD, chronic obstructive pulmonary disease; GLY, glycopyrronium; N, patients randomized; PBO, placebo; 
PTYs, patient treatment years; rr, risk ratio; s-db, safety database; sMQ, standardized MedDra Query; TIO, tiotropium.
